Inegy

Simvastatin/Ezetimibe, the active ingredient in Inegy, is a HMG‑CoA reductase inhibitor / cholesterol absorption inhibitor presented as a fixed‑dose tablet for oral use. It lowers LDL‑cholesterol and is prescribed for adults with hypercholesterolemia or mixed dyslipidemia.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across global markets. The company adheres to stringent manufacturing standards and offers comprehensive logistics solutions to meet the needs of healthcare providers in diverse regions.

Inegy, a fixed‑dose combination lipid‑lowering agent, is indicated for disorders involving elevated cholesterol levels. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol to target levels. - Mixed dyslipidemia: improves the overall lipid profile by lowering LDL and triglycerides while raising HDL. - Familial hypercholesterolemia (heterozygous): provides additional LDL‑cholesterol reduction when statin monotherapy is insufficient.

Inegy may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Myalgia: muscle aches without weakness. - Abdominal discomfort: stomach pain or cramps. - Diarrhea: loose, watery stools.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury. - Hepatotoxicity: significant elevation of liver enzymes or liver failure. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain and elevated enzymes.

Before prescribing Inegy, clinicians should consider several precautionary measures to ensure patient safety. - Liver function monitoring: assess baseline and periodic hepatic enzymes. - Muscle symptom assessment: evaluate for unexplained muscle pain or weakness. - Avoid use in active liver disease: contraindicated in patients with severe hepatic impairment. - Caution with CYP3A4 inhibitors: dose adjustment or alternative therapy may be required. - Review renal function: especially in patients with chronic kidney disease. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Inegy can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase simvastatin exposure. - Gemfibrozil: markedly raises risk of myopathy and rhabdomyolysis. - Cyclosporine: elevates both simvastatin and ezetimibe levels. - HIV protease inhibitors: potentiate statin concentrations. - Grapefruit juice: enhances simvastatin plasma concentrations.

Moderate Interactions (Monitor Closely): - Amiodarone: may increase statin levels modestly. - Warfarin: potential alteration of anticoagulant effect. - Digoxin: possible increase in serum concentrations. - Niacin: additive risk of muscle toxicity. - Antacids (aluminum‑magnesium): may reduce ezetimibe absorption.